State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

State Street Corp trimmed its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,728,144 shares of the company's stock after selling 182,547 shares during the quarter. State Street Corp owned approximately 2.67% of Kymera Therapeutics worth $81,793,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics in the third quarter worth $61,000. Quarry LP acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at approximately $95,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after acquiring an additional 504 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Kymera Therapeutics in the 2nd quarter valued at $139,000. Finally, Quest Partners LLC grew its stake in shares of Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company's stock valued at $156,000 after buying an additional 4,865 shares during the period.

Kymera Therapeutics Price Performance

KYMR traded down $0.76 during trading on Tuesday, reaching $42.30. 577,906 shares of the stock traded hands, compared to its average volume of 579,147. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -18.40 and a beta of 2.16. Kymera Therapeutics, Inc. has a fifty-two week low of $22.35 and a fifty-two week high of $53.27. The stock's 50-day simple moving average is $46.27 and its two-hundred day simple moving average is $43.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. During the same period in the prior year, the company earned ($0.90) EPS. The business's quarterly revenue was down 20.9% compared to the same quarter last year. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on KYMR shares. UBS Group decreased their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a research report on Monday, November 4th. BTIG Research initiated coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price target for the company. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Wolfe Research raised Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a report on Monday, August 26th. Finally, Guggenheim increased their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $53.88.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.